 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Hepatitis C Drug Actilon Shows PromiseMarch 28, 2006 On March 21, the biotech firm Coley Pharmaceutical Group Inc. said early data from a clinical trial of its drug Actilon showed promise in hepatitis C patients who had relapsed after previous treatments. Twelve of 14 patients (86 percent) taking Actilon with pegylated interferon and ribavirin showed early viral response; this was achieved by only eight of 15 patients (57 percent) taking pegylated interferon and ribarivin alone. The Actilon group also showed greater reduction in the number of viral copies than the control group. The trial involved a total of 74 hepatitis C patients. Associated Press 03.21.06  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
